**Effect of the NMDA receptor partial agonist, d-cycloserine, on emotional processing and autobiographical memory**

**Short Title**: Effect of DCS on emotional processing and memory

Runsen Chen 1,2, Liliana P. Capitão 1,2, Philip J. Cowen 1,2, Catherine J. Harmer 1,2\*

1Department of Psychiatry, University of Oxford, Oxford, UK

2Oxford Health NHS Foundation Trust, Warneford Hospital, University of Oxford, Oxford, UK

\*Corresponding Author: Catherine J Harmer, Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Ln, Oxford OX3 7JX, UK. Tel: +44(0) 1865618326

Email: catherine.harmer@psych.ox.ac.uk

Word count:4500

**Abstract**

**Background:** Studies suggest that d-cycloserine (DCS) may have antidepressant potential through its interaction with the glycine site of the N-Methyl-D-aspartate receptor (NMDAR); however clinical evidence of DCS’s efficacy as a treatment for depression is limited. Other evidence suggests that DCS affects emotional learning which may also be relevant for the treatment of depression and anxiety. The aim of the present investigation was to assess the effect of DCS on emotional processing in healthy volunteers and to further characterise its effects on emotional and autobiographical memory.

**Methods:** Forty healthy volunteers were randomly allocated to a single dose of 250 mg DCS or placebo in a double-blind design. Three hours later, participants performed an emotional test battery (including facial expression recognition [FERT], emotional categorisation task (ECAT), emotional recall task [EREC], attentional dot-probe task [FDOT] and emotional recognition memory task [EMEM]) and an autobiographical memory test (AMT). Also, participants performed the FERT, EREC and AMT tasks again after 24 hours in order to assess longer lasting effects of a single dose of DCS.

**Results:** DCS did not significantly affect the FERT, EMEM and FDOT performance but significantly increased emotional memory and classification for positive words versus negative words. Also, DCS enhanced the retrieval of more specific autobiographical memories, and this effect persisted at 24 hours.

**Conclusions:** These findings support the suggestion that low dose DCS increases specific autobiographical memory retrieval and positive emotional memory. Such effects make it an intriguing agent for further investigation in clinical depression, which is characterised by decreased autobiographical memory specificity and increased negative bias in memory recall. It also underscores the potential role of DCS as an adjunct to cognitive behavioural therapy in depression.

**Keywords**: DCS; memory; emotional processing; healthy volunteer; psychological treatment

**Introduction**

D-cycloserine (DCS) is an antibiotic and is used for the treatment of tuberculosis and urinary tract infections. Preclinical studies suggested that DCS appears to be a partial agonist at the glycine site of the N-methyl-D-aspartate receptor (NMDAR), behaving as an agonist at low doses but as an antagonist at higher doses (Krystal et al., 2011; Newport et al., 2015; Schade & Paulus, 2016). Activation of NMDAR requires binding of the co-agonists glutamate and glycine, and through binding to the glycine site of NMDAR, DCS can increase NMDAR-mediated activation (Scholl et al., 2014). DCS has been studied as a ‘add-on’ treatment in two placebo-controlled trials in patients with resistant depression. Positive results were obtained with a higher dose of DCS (1000mg/day) but not with a lower dose (250mg daily) (Heresco-Levy et al., 2013; Heresco-Levy et al., 2006). Furthermore, Kantrowitz, Halberstam, and Gangwisch (2015) found that daily DCS (dose increasing to 1000mg/d) prolonged the antidepressant response to ketamine in patients with treatment-resistant bipolar depression over 3 weeks.

In addition, Kim, Kushner, Yoon, Anker, and Grant (2016) and Wilhelm et al. (2008) reported that a low dose of DCS (200-250mg), given as a sole treatment, unexpectedly produced large improvements in depression ratings in patients undergoing exposure therapy for OCD. The choice of low vs. high dosages varies between studies but there is evidence suggesting that certain effects may be dose dependent. For instance, it has been suggested that DCS only has positive effects on memory when administrated at low doses, since higher doses act as an NMDAR antagonist and may therefore impair or reverse this positive effect (Flood, Morley, & Lanthorn, 1992; Lanthorn, 1994; Schade & Paulus, 2016). In humans, the effects of NMDA modulation on memory have been little investigated, but there is emerging evidence corroborating this association. The glycine blinding site of NMDAR is a target for modulating NMDA-mediated neural transmission to enhance memory (Roesler, Quevedo, Walz, Dal Pizzol, & Kapczinski, 1998). For example, Schwartz, Hashtroudi, Herting, Handerson, and Deutsch (1991) used a word-retrieval task to test the effect of a glycine site agonist on memory retrieval in healthy individuals. The authors found that a glycine pro-drug significantly increased memory retrieval and decreased the latency in both young and older adults.

A novel model of antidepressant drug action has been proposed previously by our group (Catherine J Harmer, 2010; Catherine J Harmer, Goodwin, & Cowen, 2009) which suggests that antidepressants may work by reversing the negative emotional biases in depression, which are crucial in the maintenance of this disorder. This effect is seen rapidly after antidepressant administration. For example, a single dose of the selective serotonin reuptake inhibitor (SSRI) citalopram increases the processing of positive information, such as increasing recognition of happy faces and attentional vigilance to positive stimuli (Browning, Reid, Cowen, Goodwin, & Harmer, 2007; C. Harmer et al., 2003). Further, both acute and short-term administration of the antidepressants mirtazapine and citalopram have been shown to increase the recall of positive versus negative words (Arnone, Horder, Cowen, & Harmer, 2009; Catherine J Harmer, Nicholas C Shelley, Philip J Cowen, & Guy M Goodwin, 2004). However, the effects of DCS on such measures of emotional processing have not been investigated. Given the ambiguity in results of different trials in the current literature, it is unclear whether DCS has similar antidepressant effects to conventional re-uptake blockers in acting to increase positive biases or reduce negative biases in emotional processing.

Deficit in the specificity of autobiographical memory is a cognitive marker for depression. Patients with depression have significant difficulties in recalling specific personal memories and also display overgeneralised autobiographical memory (Köhler et al., 2015). Previous studies suggested that difficulties in autobiographical memory specificity contribute to the maintenance of depressive illness, through pathways such as perceiving negative social encounters, lack of social problem solving skills, lack of self-efficacy, and feeling hopeless (Hermans, Defranc, Raes, Williams, & Eelen, 2005; Young et al., 2016). The effect of conventional antidepressants on autobiographical memory has been little studied but an investigation in healthy volunteers found that neither sertraline nor bupropion affected cued recall of autobiographical memory (Carvalho et al., 2006). DCS has not been previously tested in this respect but animal studies suggest that it facilitates long-term synaptic plasticity presumably through its effects on NMDAR receptors. A number of studies have also explored the potential for DCS to enhance retention and extinction learning in combination with Cognitive Behavioral Therapy (CBT) for anxiety disorders [21.22], though results have been mixed.

Therefore, the current study was designed to assess the effects of an acute low dose of DCS (250mg) on tasks of emotional processing and autobiographical memory in healthy volunteers. Given the finding that a single dose of the NMDAR antagonist, such as ketamine, has antidepressant effects lasting for at least 24 hours, we also explored the potential for long lasting emotional and memory effects of single dose of DCS. Hence, all participants performed emotional processing and autobiographical memory tasks after 3 and 24 hours following active drug/placebo administration. We hypothesized that DCS would enhance memory specificity and positive bias in emotional processing (specifically increase the processing of positive vs. negative stimuli in tasks measuring facial expression recognition and emotional memory) compared to placebo.

**Methods**

**Participants**

Between August and December 2018, 40 healthy volunteers aged 18-40 years enrolled in this study. A power calculation was calculated to determine the sample size. A previous study with healthy volunteers found that acute antidepressant administration reduced accuracy to detect fearful faces in healthy volunteers, with an effect size of 1.09. Informed by these data, a sample size calculation for the current between-subjects design yielded n=19 per group as the minimum sample size required to detect changes in accuracy (difference between two independent means: two tailed, alpha=0.05; power=0.9) (Catherine J Harmer et al., 2004). Inclusion criteria were: 1) body mass index (BMI) within the range of 19-30 kg/m2; 2) no current or past history of any psychiatric disorders, as assessed using the Structured Clinical Interview (SCID) for DSM-5; 3) no lifetime history of significant physical disease; 4) sufficiently fluent in English; 5) non or light smoker (<5 cigarettes a day), low caffeine use (<5 cups a day) or low alcohol use (<30 units per week); 6) abstinence from any central nervous system (CNS) active medication during the last 6 weeks; 7) female participants must not be pregnant, breastfeeding or planning pregnancy; 8) no current or past history of drug or alcohol dependency.

All procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Ethical approval for this current study was obtained from the Central University Research Ethics Committee (CUREC) (Oxford University) and all participants gave written and verbal consent prior to participation in the study. The study was retrospectively registered on ClinicalTrials.gov (Identifier: NCT03961464).

**Procedure**

This was a double-blind, placebo-controlled, randomised design. All participants were required to complete baseline assessments including the Eysenck Personality Questionnaire (EPQ) (Eysenck & Eysenck, 1975), the Spot-the-Word (STW) test to assess verbal intelligence (Baddeley, Emslie, & Nimmo‐Smith, 1993), the Beck Depression Inventory (BDI) (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961) and the Trait Anxiety Scale (STAI-T) (Speilberger, Gorsuch, & Lushene, 1970).

Eligible participants arrived at the lab in the morning and were randomised to receive either a single dose of 250mg DCS or placebo. Participants were required to abstain from alcohol and caffeine from 12 h before testing and fast for 2 h in the morning of the testing day. The randomisation code was generated by a member of our group who is not otherwise involved in the study. DCS is thought to have a half-life of 8 h to 15 h (Patel et al., 2011). Given that plasma peak levels for DCS are reached within 3-4 hours (Scholl et al., 2014), all participants were tested 3 hours after drug administration. During the 3 hours between dosing and testing, participants were asked to stay in the testing room, but they were free to engage in an activity of their choice, e.g. reading a book, working, or using their laptop.

Participants filled out the following measures before taking the active drug or placebo: Spielberger State Anxiety Inventory (STAI-S) (Spielberger & Gorsuch, 1983), Positive and Negative Affect Schedule (PANAS) (Watson, Clark, & Tellegen, 1988), the Befindlichkeits Scale (BFS) (Von Zerssen & Bf-SR, 2011), as well as Bond-Lader visual analogue scales (VAS) to assess side effects and subjective mood ratings. These questionnaires were repeated 3 hours after drug administration and again at the end of the third study visit (24 hours after drug administration). At 3 hours after drug administration, participants completed the following tasks from the Emotional Test Battery: Facial Expression Recognition Task [FERT], Emotional Categorization Task [ECAT], Facial Dot-Probe Task [FDOT], Emotional Recall Task [EREC] and Emotional Recognition Memory Task [EMEM], as well as an Autobiographical memory task (AMT) (see below) and a cognitive stress task. The whole process (study visit 2) occurred over approximately 5 hours and the tasks were taken in the above order. The results of stress task will be reported in a separate paper. In order to examine longer lasting emotional effects, participants returned to the lab after 24 hours and completed the FERT, EREC and AMT task once again.

**Emotional Test Battery**

The Emotional Test Battery (ETB) includes several validated measures of emotional processing (Harmer D Phil et al., 2009). These tasks have been described in full in previous publications (Catherine J Harmer et al., 2009; Warren, Cowen, & Harmer, 2018). In brief, the tasks involved in the ETB are listed below. FERT presents individual facial expression in seven different emotions (neutral, fear, anger, sadness, disgust, happiness, surprise). Each emotional expression is conveyed with varying levels of intensity and participants are required to recognise these different emotions in stimulus faces. ECAT presents the participants with sixty personality characteristics that are categorised as either extremely disagreeable (e.g. bossy, crude, scornful) or agreeable (e.g. enthusiastic, honest, thoughtful). Participants are required to imagine themselves overhearing someone describing themselves using each of the words and to judge as quickly and accurately as possible whether they would like or dislike to be described with each of the personality words. FDOT tests attention to positive versus negative emotion using happy and fearful faces. The accuracy and the time needed to correctly identify the probe orientation were recorded. Vigilance scores were calculated for emotional pairs by subtracting reaction times in incongruent trials (i.e. the probe appears behind the neutral expression) from congruent trials (i.e. the probe appears behind the emotional expressions) as the index for attentional biases to emotional information. EREC was tested 15-minutes after the completion of the ECAT. Participants were asked to recall as many words they saw in the previous task as possible within four minutes. EMEM was administered after a 19-minute long distraction period from ECAT, participants were presented with personality words from the ECAT and also another set of positive and negative personality words (which had not been seen before) and asked to indicate whether they classified each word from ECAT as familiar or unfamiliar.

**Autobiographical memory task**

In the autobiographical memory task (J. M. Williams & Broadbent, 1986; J. M. G. Williams et al., 1996), memory cues were presented visually on a computer screen in a fixed order, with positive, negative, and neutral words appearing. Participants were exposed twice with parallel version of AMT cues word in day 1 and day 2. All cues words (positive, negative and neutral) were matched for word imageability, emotionality and frequency. The positive words were: successful, smile, gift, relaxed, compliment, excited (day 1), and laughing, friendly, proud, helpful, enthusiastic and pleased (day 2). The negative words were: danger, mistake, angry, tears, guilty, disappointed (day 1), and argument, failure, nervous, blame, lonely, embarrassed (day 2). The neutral words were: garden, conversation, late, package, advice, look (day 1), and shop, library, make/made, walking, traveling and listening (day 2). Each word was presented only once. For each cue word, participants are required to recall an important or trivial event that occurred recently or a long time ago within 1 minute, but the event should be something that happened at a particular time/day and particular place and the event must have lasted less than 1 day. Participants were told that they should not recall the same event for more than one cue word. Also, on day 2, participants were told that the memory they recalled could not be the same as any response from day 1. Correct and incorrect examples were provided. Three practice cues words (tree, chair and car) and feedback were given. Responses were tape-recorded for subsequent coding. The memories were coded (Haddad, Williams, McTavish, & Harmer, 2009) as (1) specific memories: an event that occurred on a particular time/day and particular place; (2) extended memories: an event that lasted more than a day; (3) categorical memories: an event that occurred repeatedly; (4) semantic memories: reported something associated with the cue word rather than a memory; (5) no response (omission); (6) repeated the same response from different cue words. Extended and categorical memories were combined to form the overgeneral memory type. A second independent rater coded 20% of responses; the mean kappa coefficient of reliability on specific memories was 0.97.

**Statistical analyses**

All analyses were performed using the IBM SPSS Software, version 21. For all tasks, any scores observed to be greater than 3 standard deviations from the group mean were considered extreme outliers and excluded from the analysis (Thomas, Higgs, & Dourish, 2016). It was only necessary to exclude one participant due to this rule in the Emotional Categorisation Task (ECAT). The baseline measurements (age, education years, BMI, EPQ, verbal IQ, STAI-T) as well as the mood and anxiety scales administered on day 2 (BFS, STAI-S, PANAS, VAS) were analysed using independent sample t-tests. Mood, anxiety and side effects scales (BFS, STAI-S, PANAS, VAS) on day 1 were analysed using repeated measures ANOVA, with time (pre-post drug/placebo) and group condition (DCS/placebo) as within-and between-subjects factors, respectively. The data from AMT and each task of ETB was analysed using repeated measures ANOVA with treatment group (DCS and placebo) as the between-subject factor and different within-subject factors depending on the task (FERT: facial expression; ECAT/EREC/EMEM/AMT: word valence; FDOT: facial expression and masking). Significant interactions between time and group were further examined using between-group independent sample t-tests.

**Results**

**Baseline characteristics**

The groups were well matched in terms of age, gender, BMI, Verbal IQ, STAI-T (trait anxiety), EPQ and depression symptoms (See Table 1). The groups were also comparable in their scores on the STAI-S (state anxiety), PANAS and VAS (mood levels and side effects).

**Changes in subjective mood**

There were no significant effects of group or time by group interaction on any of the questionnaires measuring subjective mood and anxiety such as the BFS Scale, STAI-S and PANAS (all *p* > 0.5). There were also no significant main effects of group or time by group interactions on subjective symptoms (assessed by Visual Analogue Scale, VAS) (all *p* > 0.05). A few side effects were reported, but there were no significant different between the DCS and placebo groups (all *p* > 0.05) (See Table 2).

**Facial expression recognition (FERT)**

There were no significant effects of DCS on facial expression recognition in terms of accuracy, misclassifications and reaction times (*p* values > 0.2).

**Emotional Categorization Task (ECAT)**

One participant was excluded from this analysis due to extreme reaction times (above 3 sd from the group mean). There was no main effect of group in the reaction times to categorise self-referent personality words (F(1,37) = 0.012, *p* = 0.913) or emotional valence x group interaction (F(1,37) = 3.818, *p* = 0.913). However, there was a trend for a significant interaction between treatment and valence, driven by a higher proportion of positive versus negative words accurately categorised in the DCS versus placebo group (group condition x word valence: F(1,37) = 3.818, *p* = 0.058).

**Emotional Recall Task (EREC)**

The EREC is a free recall task during which participants are required to remember as many of the positive and negative personality words from the ECAT as they can in 4 minutes. DCS increased the proportion of positive versus negative words accurately compared to the placebo group (F(1, 38) = 5.391, *p* = 0.026) (See Figure 1).

**Emotional Recognition Memory task (EMEM)**

EMEM includes the personality words from the ECAT and previously unseen words that participants are required to classify as familiar or unfamiliar. No significant treatment effects on word recognition accuracy or reaction times were found for this task (all *p* > 0.1).

**Facial Dot-Probe Task (FDOT)**

A three-factor ANOVA among treatment (DCS and placebo) x masking (mask, unmasked) x valence (happy, fear) on vigilance scores yielded no significant effect of valence, masking or treatment and no significant interactions for attentional vigilance (*p* values > 0.2).

**Autobiographical memory task (AMT)**

When considering autobiographic specific events, there was no significant interaction between the treatment condition and the three emotional categories (F(1,38) = 0.852, *p* = 0.431). However, participants on DCS recalled more specific events overall, regardless of the condition (F(1,38) = 15.948, *p* < 0.001) (See Figure 2).

**Day 2**

**Changes in subjective mood**

There were no significant effects of group on any of the questionnaires measuring subjective mood and anxiety by BFS Scale, STAI-S and Positive and PANAS on day 2 (all *p* > 0.05). There were also no significant effects of group on mood levels and side effects ratings as assessed by VAS (all *p* > 0.05) (see Table 3).

**Facial expression recognition (FERT)**

There were no effects of DCS on facial expression recognition in terms of accuracy, misclassification and reaction times (*p* values >0.3).

**Emotional Recall Task (EREC)**

There were no significant effects of DCS on the proportion of words recalled (*p* values >0.1).

**Autobiographical memory task (AMT)**

Similarly to day 1, when considering autobiographical specific events, there was no significant interaction between the treatment condition and the three emotional categories (F（1,38）= 0.223, *p* = 0.800). However, there was a significant main effect of treatment (F（1,38）= 5.779, *p =* 0.021), with participants on DCS recalling more specific events than placebo, regardless of the category (See Figure 2).

**Correlation analysis**

Given that the participants showed an enhancing effect in the retrieval of more specific autobiographical memories at 2 h and 24 h, correlations were conducted between total scores on these two sessions in the DCS group. A significant positive correlation was observed (Pearson correlation=0.669, N=20, *p*=0.001).

**Discussion**

DCS significantly enhanced autobiographical memory specificity when compared to placebo at 3 and 24 hours following treatment. DCS increased positive bias in emotional word categorisation and subsequent free recall, however this effect did not extend to other tasks measuring emotional recognition, facial expression recognition or attentional vigilance.

Our results indicated that DCS, when likely to be acting as an NMDA receptor glycine site agonist (in the low dose used here), increases the autobiographical memory retrieval of specific events. Depression is associated with deficits in the retrieval of autobiographic memories, especially specific events (Köhler et al., 2015), which has been regarded as an aberrant coping style serving to maintain the disorder (Hermans et al., 2005; Young et al., 2016). There is also evidence suggesting that increases in memory specificity are associated with improvement in depressive symptoms, rumination and cognitive avoidance in depressed patients (Neshat-Doost et al., 2013; Raes, Williams, & Hermans, 2009).

Importantly, the effect seen here on autobiographical memory is consistent with pre-clinical evidence suggesting that agents acting to facilitate NMDA receptor activity enhance memory. The NMDA glutamate receptor is an important component of memory formation, which is modelled by long term potentiation (LTP) in the hippocampus and amygdala (Rezvani, 2006). Animal studies have shown that NMDA receptors play an important role in different types of learning and memory, including spatial working memory and long-term (reference) memory (Shapiro & Caramanos, 1990). Importantly, previous rodent studies have shown that acute administration of DCS facilitates acquisition and subsequent memory retrieval (Flood et al., 1992; Quartermain, Mower, Rafferty, Herting, & Lanthorn, 1994). Complementary studies suggest that NMDA receptor antagonists such as ketamine could result in learning and memory impairment (Morgan, Mofeez, Brandner, Bromley, & Curran, 2004; Rezvani, 2006), although this evidence remains equivocal (Zhang & Ho, 2016). Becker et al. (2017) found that the effects of ketamine on memory recognition and memory enhancement for negative information were less disrupted during encoding vs. subsequent recall in healthy volunteers. Interestingly, a recent study by (Radford et al., 2018)) found that sub-anesthetic intravenous (IV) ketamine infusion dose-dependently enhanced fear memory retrieval, delayed fear extinction and increased fear recall in rats. However, the same dose of ketamine via intraperitoneal (IP) injection facilitated fear memory extinction after auditory fear conditioning. This study therefore suggests that the differential effects of ketamine may depend on the route and duration of administration.

Clinically, there is evidence suggesting that DCS augments response to CBT for anxiety and related disorders (Otto, Basden, Leyro, McHugh, & Hofmann, 2007; Otto et al., 2010). For instance, a recent meta-analysis found that DCS is superior to placebo in augmenting the effects of CBT in patients with anxiety disorders, both at post-treatment and at follow-up (Mataix-Cols et al., 2017). DCS has been found to enhance extinction learning in both human and animal studies (Richardson, Ledgerwood, & Cranney, 2004), therefore it is possible that DCS enhances the CBT effects through enhancing extinction learning, which is a critical element of CBT for anxiety. There is limited evidence investigating the effects of DCS as an adjunct treatment when combined with CBT for depression. However, Wilhelm et al. (2008) found that treatment with low dose DCS (200-250mg) unexpectedly produced large improvements in depression ratings in patients undergoing exposure therapy for obsessive compulsive disorder (OCD), and these effects were seen independently of improvement in OCD symptoms. A study with a similar design by Kim et al. (2016) also found an unexpected improvement in depressive symptoms in patients with OCD. As noted by Kim and colleagues, these findings raise the intriguing possibility that low-dose DCS may display antidepressant properties. It would therefore be important for future studies to test the effects of DCS as an adjunct drug therapy when combined with CBT for depression. There are CBT approaches specifically designed to alleviate difficulties in retrieving specific autobiographical memories shown by patients with depression (McBride, Segal, Kennedy, & Gemar, 2007; Raes et al., 2009), and it would be worth investigating whether DCS could enhance these effects.

In this study, DCS also affected self-referential processing. DCS appears to significantly increase the categorisation and subsequent recall of positive versus negative personality words. This effect is also seen with traditional antidepressant drugs. For instance, the commonly prescribed drugs citalopram and reboxetine have both been shown to increase the relative recall of positive (versus negative) personality words, using the same task as used here (C. J. Harmer, S. A. Hill, M. J. Taylor, P. J. Cowen, & G. M. Goodwin, 2003; C. J. Harmer, N. C. Shelley, P. J. Cowen, & G. M. Goodwin, 2004; Harmer D Phil et al., 2009). In addition, venlafaxine has been shown to enhance positive bias during social and emotional evaluations when administered before learning. In contrast, the NMDAR antagonist ketamine can abolish memory for previously learnt negative biases but does not produce positive affective information biases in newly-learnt information (Stuart, Butler, Munafò, Nutt, & Robinson, 2015). It is noteworthy that recurrent negative thoughts (such as self-blame and feeling hopeless/worthless) are important cognitive markers in depression and suicidal behaviour (Grunebaum et al., 2005; Northoff, 2007). Increasing positive self-referential processing (use of positive information for self-description) is another core therapeutic component for cognitive therapy for depression (Segal & Gemar, 1997; Tarrier, 2010) and might be enhanced by DCS treatment.

Our study also revealed that the autobiographical memory enhancing effect of DCS persisted for 24 hours after drug administration. A number of animal experimental studies demonstrated that DCS improves memory consolidation for new learning normally 24 hours after training (Goff, 2012). For instance, a rodent study found that a single dose of DCS given within 30 minutes of extinction training increased the retention of fear extinction 24 hours later by approximately 3-fold (Parnas, Weber, & Richardson, 2005). Also, a rodent fear extinction model found that DCS improves memory consolidation for new learning assessed 24 hours after training, but did not show any effect on learning performance during the training itself (Santini, Muller, & Quirk, 2001). These findings are interesting in light of a study in patients with panic disorder in which DCS produced effects on emotional neural processing 24 hours after administration (Reinecke, Nickless, Browning, & Harmer, 2018). A recent review article proposed that the reconsolidation of autobiographical memories in patients with depression may represent a novel therapeutic target, and the authors suggested that future research should explore the modulation of reconsolidation of distressing autobiographical memory following antidepressant treatment for depression (Köhler et al., 2015). DCS might also be a pharmacological candidate for this approach.

It is important to specify that this memory-enhancing effect 24 hours after DCS administration was only seen with the autobiographical memory task and not with the memory word recall. It is possible that the personal and specific elements of the autobiographical task may have enhanced the effects of DCS (as these effects were also only seen with specific but not general memories), but future studies with different paradigms are needed to understand what are the key memory elements that are associated with these effects of DCS (e.g., personal relevance, specificity of the memory, among others).

In addition, it was previously found that an acute dose of the SSRI citalopram (20 mg) increased facial recognition of happy faces. Also, in the short-term, citalopram increases the recognition of fearful faces and increases the startle response (Browning et al., 2007; C. Harmer et al., 2003), which is consistent with clinical findings suggesting that early stage SSRI treatment may increase anxiety (Kent, Coplan, & Gorman, 1998). Noradrenaline reuptake inhibitors such as reboxetine also increased the recognition of positive facial expressions and the speed of reaction time in responding to positive personality words, however there was no significant effect on fear processing (Catherine J Harmer, Simon A Hill, Matthew J Taylor, Philip J Cowen, & Guy M Goodwin, 2003). Similar findings emerged using bupropion, which is an inhibitor of dopamine and noradrenaline reuptake (Walsh et al., 2018). However, the present study revealed no significant effects of DCS similar to the above studies on either facial recognition or fear processing changes. Thus, the current study suggests that low doses of DCS, presumably acting as a glycine site agonist, did not show the broad range of positive effects on emotional processing seen with conventional antidepressants.

It is possible that the positive bias effect seen with DCS is specific to the encoding and retrieval of memory. Such an effect would be consistent with the modulation of glutamate receptors by DCS. It should be noted, however, that no significant effects were seen in the memory recognition task, although this is consistent with previous antidepressant drug studies showing that the free memory recall has higher sensitivity to antidepressant medications (C. J. Harmer, Cowen, & Goodwin, 2011). Indeed, the lower level of difficulty of the memory recognition paradigm vs. free recall may allow for less variability in performance, which would be important to detect more subtle drug effects. Further investigation is needed to clearly delineate the effects of DCS on cognitive functions relevant to depression, including different types of memory.

There are several limitations to the present study. First, the autobiographical memory task was not tested at baseline before drug administration, and it is possible that baseline differences in memory performance may have existed between the groups independent of the effects of DCS. However, the baseline demographic information revealed that the treatment and control groups were well matched, which should minimise this confounding effect. Second, the significant findings within the autobiographical memory task cannot exclude the possibility of a ceiling effect, as all groups recalled a high percentage of specific autobiographical memories. Third, the plasma levels of DCS were not measured, so it would be helpful for future studies to investigate if the effects of DCS vary depending on the subjects’ plasma levels. Fourth, the study was powered to detect a large effect size (based on a single observed difference from a previous study) and was therefore underpowered to detect small to moderate effect sizes. Finally, this study did not examine other memory tasks, such as working and verbal memory, which could have provided a more comprehensive exploration of the memory enhancing effects of DCS. Future studies should extend the current findings into patients with depression. It would also be helpful to examine the neural substrates of the effect of DCS on memory using functional neuroimaging. In addition, this is an experimental medicine study, which was registered retrospectively. We recognise the important of pre-registering all interventional studies (not only clinical trials) and therefore we have registered the study prior to data analysis. We did not change the protocol after the study started.

**Conclusion**

To the best of our knowledge, this is the first study to provide evidence that low dose DCS improves the retrieval of specific autobiographic memories. It also suggests that DCS increases the recall of positive vs. negative words. DCS may have particular utility when combined with psychological therapies aimed at increasing specific personal memories and positive self-referential processing. The potential antidepressant-like properties of DCS are therefore worth exploring in future studies.

**Acknowledgements**

We thank Shaoling Zhong for being a second independent rater for the analysis of the autobiographical memory task. We thank Lucy Wright and Kate Partridge for help in data collection; Claire Williams and Ann Sharpley for help with encapsulation and randomisation; and Michael Browning, Beata Godlewska, Tarek Zghoul and Paul Harrison for medical cover.

**Financial support**

This study was supported by the China Scholarship Council (CSC) & NIHR Oxford Health Biomedical Research Centre (OH BRC). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Conflicts of interest**

L.C. served as a consultant to P1vital, a contract research organization that runs industry-sponsored experimental medicine studies in academic departments. C.H. receives consultancy fees from and has shares in P1vital. She has also received consultancy fees from Lundbeck, Johnson and Johnson (J&J) and Servier, and has received grant income from J&J and UCB. The other authors have no conflict of interest to declare.

**Ethical standards**

“The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.” All participants were informed of the objective of the study and gave written consent before the investigation.

**References**

Arnone, D., Horder, J., Cowen, P., & Harmer, C. (2009). Early effects of mirtazapine on emotional processing. *Psychopharmacology, 203*(4), 685.

Baddeley, A., Emslie, H., & Nimmo‐Smith, I. (1993). The Spot‐the‐Word test: A robust estimate of verbal intelligence based on lexical decision. *British Journal of Clinical Psychology, 32*(1), 55-65.

Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. *Archives of general psychiatry, 4*(6), 561-571.

Becker, B., Steffens, M., Zhao, Z., Kendrick, K. M., Neumann, C., Weber, B., . . . Hurlemann, R. (2017). General and emotion-specific neural effects of ketamine during emotional memory formation. *Neuroimage, 150*, 308-317.

Browning, M., Reid, C., Cowen, P., Goodwin, G., & Harmer, C. (2007). A single dose of citalopram increases fear recognition in healthy subjects. *Journal of Psychopharmacology, 21*(7), 684-690.

Carvalho, A. F., Köhler, C. A., Cruz, E. P., Stürmer, P. L., Reichman, B. P., Barea, B. M., . . . Chaves, M. L. (2006). Acute treatment with the antidepressants bupropion and sertraline do not influence memory retrieval in man. *European Archives of Psychiatry and Clinical Neuroscience, 256*(5), 320-325.

Eysenck, H. J., & Eysenck, S. B. G. (1975). *Manual of the Eysenck Personality Questionnaire (junior and adult)*: Hodder and Stoughton.

Flood, J. F., Morley, J. E., & Lanthorn, T. H. (1992). Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. *European journal of pharmacology, 221*(2-3), 249-254.

Goff, D. C. (2012). D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. *Schizophrenia Bulletin, 38*(5), 936-941.

Grunebaum, M. F., Keilp, J., Li, S., Ellis, S. P., Burke, A. K., Oquendo, M. A., & Mann, J. J. (2005). Symptom components of standard depression scales and past suicidal behavior. *Journal of affective disorders, 87*(1), 73-82.

Haddad, A. D., Williams, J. M. G., McTavish, S. F., & Harmer, C. J. (2009). Low-dose tryptophan depletion in recovered depressed women induces impairments in autobiographical memory specificity. *Psychopharmacology, 207*(3), 499-508.

Harmer, C., Bhagwagar, Z., Perrett, D., Völlm, B., Cowen, P., & Goodwin, G. (2003). Acute SSRI administration affects the processing of social cues in healthy volunteers. *Neuropsychopharmacology, 28*(1), 148.

Harmer, C. J. (2010). Antidepressant drug action: a neuropsychological perspective. *Depression and anxiety, 27*(3), 231-233.

Harmer, C. J., Cowen, P. J., & Goodwin, G. M. (2011). Efficacy markers in depression. *J Psychopharmacol, 25*(9), 1148-1158. doi:10.1177/0269881110367722

Harmer, C. J., Goodwin, G. M., & Cowen, P. J. (2009). Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. *The British Journal of Psychiatry, 195*(2), 102-108.

Harmer, C. J., Hill, S. A., Taylor, M. J., Cowen, P. J., & Goodwin, G. M. (2003). Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. *American Journal of Psychiatry, 160*(5), 990-992.

Harmer, C. J., Hill, S. A., Taylor, M. J., Cowen, P. J., & Goodwin, G. M. (2003). Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. *Am J Psychiatry, 160*(5), 990-992. doi:10.1176/appi.ajp.160.5.990

Harmer, C. J., Shelley, N. C., Cowen, P. J., & Goodwin, G. M. (2004). Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. *American Journal of Psychiatry, 161*(7), 1256-1263.

Harmer, C. J., Shelley, N. C., Cowen, P. J., & Goodwin, G. M. (2004). Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. *Am J Psychiatry, 161*(7), 1256-1263. doi:10.1176/appi.ajp.161.7.1256

Harmer D Phil, C. J., O’Sullivan, U., Favaron, E., Massey-Chase, R., Ayres, R., Reinecke, A., . . . Cowen, P. J. (2009). Effect of acute antidepressant administration on negative affective bias in depressed patients. *American Journal of Psychiatry, 166*(10), 1178-1184.

Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013). A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. *International Journal of Neuropsychopharmacology, 16*(3), 501-506.

Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006). Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. *Journal of affective disorders, 93*(1-3), 239-243.

Hermans, D., Defranc, A., Raes, F., Williams, J. M. G., & Eelen, P. (2005). Reduced autobiographical memory specificity as an avoidant coping style. *British Journal of Clinical Psychology, 44*(4), 583-589.

Kantrowitz, J. T., Halberstam, B., & Gangwisch, J. (2015). Single-dose ketamine followed by daily d-cycloserine in treatment-resistant bipolar depression. *The Journal of clinical psychiatry, 76*(6), 737-738.

Kent, J. M., Coplan, J. D., & Gorman, J. M. (1998). Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. *Biological psychiatry, 44*(9), 812-824.

Kim, S. W., Kushner, M. G., Yoon, G., Anker, J., & Grant, J. E. (2016). Low-Dose d-Cycloserine for depression? *Journal of Clinical Psychiatry, 77*(8), e1007.

Köhler, C. A., Carvalho, A. F., Alves, G. S., McIntyre, R. S., Hyphantis, T. N., & Cammarota, M. (2015). Autobiographical memory disturbances in depression: A novel therapeutic target? *Neural Plasticity, 2015*.

Krystal, J. H., Petrakis, I. L., Limoncelli, D., Nappi, S. K., Trevisan, L., Pittman, B., & D'souza, D. C. (2011). Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence. *Neuropsychopharmacology, 36*(3), 701.

Lanthorn, T. (1994). D-cycloserine: agonist turned antagonist. *Amino Acids, 6*(3), 247-260.

Mataix-Cols, D., De La Cruz, L. F., Monzani, B., Rosenfield, D., Andersson, E., Pérez-Vigil, A., . . . Dunlop, B. W. (2017). D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. *Jama Psychiatry, 74*(5), 501-510.

McBride, C., Segal, Z., Kennedy, S., & Gemar, M. (2007). Changes in autobiographical memory specificity following cognitive behavior therapy and pharmacotherapy for major depression. *Psychopathology, 40*(3), 147-152. doi:10.1159/000100003

Morgan, C. J., Mofeez, A., Brandner, B., Bromley, L., & Curran, H. V. (2004). Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. *Neuropsychopharmacology, 29*(1), 208.

Neshat-Doost, H. T., Dalgleish, T., Yule, W., Kalantari, M., Ahmadi, S. J., Dyregrov, A., & Jobson, L. (2013). Enhancing autobiographical memory specificity through cognitive training: An intervention for depression translated from basic science. *Clinical Psychological Science, 1*(1), 84-92.

Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., . . . Treatments. (2015). Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. *American Journal of Psychiatry, 172*(10), 950-966.

Northoff, G. (2007). Psychopathology and pathophysiology of the self in depression—neuropsychiatric hypothesis. *Journal of affective disorders, 104*(1-3), 1-14.

Otto, M. W., Basden, S. L., Leyro, T. M., McHugh, R. K., & Hofmann, S. G. (2007). Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. *CNS spectrums, 12*(1), 51-61.

Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., . . . Pollack, M. H. (2010). Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. *Biological psychiatry, 67*(4), 365-370.

Parnas, A. S., Weber, M., & Richardson, R. (2005). Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. *Neurobiology of learning and memory, 83*(3), 224-231.

Patel, D. S., Sharma, N., Patel, M. C., Patel, B. N., Shrivastav, P. S., & Sanyal, M. (2011). Development and validation of a selective and sensitive LC–MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. *Journal of Chromatography B, 879*(23), 2265-2273.

Quartermain, D., Mower, J., Rafferty, M. F., Herting, R. L., & Lanthorn, T. H. (1994). Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. *European journal of pharmacology, 257*(1-2), 7-12.

Radford, K. D., Park, T. Y., Jaiswal, S., Pan, H., Knutsen, A., Zhang, M., . . . Choi, K. H. (2018). Enhanced fear memories and brain glucose metabolism (18 F-FDG-PET) following sub-anesthetic intravenous ketamine infusion in Sprague-Dawley rats. *Translational psychiatry, 8*(1), 263.

Raes, F., Williams, J. M. G., & Hermans, D. (2009). Reducing cognitive vulnerability to depression: A preliminary investigation of MEmory Specificity Training (MEST) in inpatients with depressive symptomatology. *Journal of behavior therapy and experimental psychiatry, 40*(1), 24-38.

Reinecke, A., Nickless, A., Browning, M., & Harmer, C. J. (2018). A Randomized Double-Blind Trial of D-Cycloserine Augmented Single-Session Exposure Therapy for Anxiety: Neurocognitive Mechanisms. *Available at SSRN 3253314*.

Rezvani, A. H. (2006). Involvement of the NMDA System in Learning and Memory. *Animal models of cognitive impairment*, 37-48.

Richardson, R., Ledgerwood, L., & Cranney, J. (2004). Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. *Learn Mem, 11*(5), 510-516. doi:10.1101/lm.78204

Roesler, R., Quevedo, J., Walz, R., Dal Pizzol, F., & Kapczinski, F. (1998). Drugs acting at the glycine site on the NMDA receptor as cognitive enhancers in patients with Alzheimer's disease. *Neurology, 50*(4), 1195-1195.

Santini, E., Muller, R. U., & Quirk, G. J. (2001). Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. *Journal of Neuroscience, 21*(22), 9009-9017.

Schade, S., & Paulus, W. (2016). D-Cycloserine in neuropsychiatric diseases: a systematic review. *International Journal of Neuropsychopharmacology, 19*(4).

Scholl, J., Günthner, J., Kolling, N., Favaron, E., Rushworth, M. F., Harmer, C. J., & Reinecke, A. (2014). A role beyond learning for NMDA receptors in reward-based decision-making—a pharmacological study using d-cycloserine. *Neuropsychopharmacology, 39*(12), 2900.

Schwartz, B., Hashtroudi, S., Herting, R., Handerson, H., & Deutsch, S. (1991). Glycine prodrug facilitates memory retrieval in humans. *Neurology, 41*(9), 1341-1341.

Segal, Z. V., & Gemar, M. (1997). Changes in cognitive organisation for negative self-referent material following cognitive behaviour therapy for depression: A primed Stroop study. *Cognition & Emotion, 11*(5-6), 501-516.

Shapiro, M. L., & Caramanos, Z. (1990). NMDA antagonist MK-801 impairs acquisition but not performance of spatial working and reference memory. *Psychobiology, 18*(2), 231-243.

Speilberger, C., Gorsuch, R., & Lushene, R. (1970). STAI Manual. Palo Alto. In: CA: Consulting Psychologist Press.

Spielberger, C. D., & Gorsuch, R. L. (1983). *State-trait anxiety inventory for adults: sampler set: manual, test, scoring key*: Mind Garden.

Stuart, S. A., Butler, P., Munafò, M. R., Nutt, D. J., & Robinson, E. S. (2015). Distinct neuropsychological mechanisms may explain delayed-versus rapid-onset antidepressant efficacy. *Neuropsychopharmacology, 40*(9), 2165.

Tarrier, N. (2010). Broad minded affective coping (BMAC): A “positive” CBT approach to facilitating positive emotions. *International Journal of Cognitive Therapy, 3*(1), 64-76.

Thomas, J. M., Higgs, S., & Dourish, C. T. (2016). Test–retest reliability and effects of repeated testing and satiety on performance of an Emotional Test Battery. *Journal of clinical and experimental neuropsychology, 38*(4), 416-433.

Von Zerssen, D., & Bf-SR, P. F. (2011). The Befindlichkeits Scale–Revised. *Göttingen: Hogrefe*.

Walsh, A., Huneke, N., Brown, R., Browning, M., Cowen, P., & Harmer, C. (2018). A dissociation of the acute effects of bupropion on positive emotional processing and reward processing in healthy volunteers. *Frontiers in psychiatry, 9*, 482.

Warren, M. B., Cowen, P. J., & Harmer, C. J. (2018). Subchronic treatment with St John’s wort produces a positive shift in emotional processing in healthy volunteers. *Journal of Psychopharmacology*, 0269881118812101.

Watson, D., Clark, L. A., & Tellegen, A. (1988). Development and validation of brief measures of positive and negative affect: the PANAS scales. *Journal of personality and social psychology, 54*(6), 1063.

Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., . . . Rauch, S. L. (2008). Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. *American Journal of Psychiatry, 165*(3), 335-341.

Williams, J. M., & Broadbent, K. (1986). Autobiographical memory in suicide attempters. *Journal of abnormal psychology, 95*(2), 144.

Williams, J. M. G., Ellis, N. C., Tyers, C., Healy, H., Rose, G., & Macleod, A. K. (1996). The specificity of autobiographical memory and imageability of the future. *Memory & cognition, 24*(1), 116-125.

Young, K. D., Drevets, W. C., Dantzer, R., Teague, T. K., Bodurka, J., & Savitz, J. (2016). Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression. *Brain, behavior, and immunity, 56*, 335-342.

Zhang, M. W., & Ho, R. (2016). Controversies of the Effect of Ketamine on Cognition. *Frontiers in psychiatry, 7*, 47.

**Figure.1.** Performance in Emotional Recall Task and comparison participants receiving DCS or placebo a

A close up of a piece of paper

Description automatically generated

a Comparison for positive stimuli versus negative stimuli (mean number of items recalled) between participants receiving DCS and placebo.

**Figure.2.** Performance in Autobiographical Memory Task and comparison participants receiving DCS or placebo a

A screenshot of a cell phone

Description automatically generatedA close up of a piece of paper

Description automatically generated

a Comparison for total specific memories (number of items retrieved) following 3 hours (Day 1) and 24 hours (Day 2) DCS or placebo administration.

**Table.1.** Baseline demographic and baseline mood scores

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | DCS (n=20) | Placebo (n=20) | T | Significance *p* |
| Age | 23.45(4.09) | 22.7(3.3) | 0.637 | 0.528 |
| Gender, n |  |  |  |  |
| Male | 10 | 9 |  |  |
| Female | 10 | 11 |  |  |
| Year of education | 16.75(2.47) | 16.7(1.92) | 0.071 | 0.943 |
| EPQ neuroticism | 7.45(5.12) | 6.65(4.25) | 0.537 | 0.594 |
| EPQ psychoticism | 4.35(3.34) | 3.6(2.11) | 0.848 | 0.402 |
| EPQ extraversion | 13.25(4.84) | 14.9(3.74) | -1.206 | 0.235 |
| BMI | 22.59 (2.20) | 22.81(2.64) | -0.321 | 0.772 |
| BDI  Verbal IQ | 3.15 (3.05)  62.9 (12.77) | 2.7 (3.48)  66.75 (12.23) | 20 (7.4)  -0.974 | 0.666  0.336 |
| STAI-T | 34.8(7.73) | 33.55(8.94) | 0.473 | 0.639 |

EPQ, Eysenck Personality Questionnaire; BFS, Befindlichskeit Scale; BDI, Beck Depression Inventory; STAI, Spielberg State Trait Anxiety Inventory-Trait

**Table.2.** Mood, anxiety and side-effects ratings for day 1

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | DCS | | Placebo | |
|  | Pre | Post | Pre | Post |
| BFS | 12.3(11.2) | 14.95(12.63) | 11.9(9.18) | 13.3(11.93) |
| State Anxiety  (STAI) | 29(7.03) | 29(7.28) | 28.3(6.48) | 27.95(5.70) |
| VAS Happy | 70.4(14.7) | 65.95(18.96) | 67.35(12.25) | 64.85(17.18) |
| VAS Sad | 8.2(9.34) | 8.7(13.19) | 8.35(12.39) | 6.25(9.79) |
| VAS Interested | 72.25(17.80) | 64.4(24.05) | 71.05(15.24) | 61.55(18.44) |
| VAS Anxious | 13.4(15.76) | 11.15(15.23) | 11.7(14.27) | 4.6(6.85) |
| VAS Stressed | 16(13.35) | 7.65(8.79) | 13.55(12.58) | 11.1(16.14) |
| VAS Hostile | 5.25(9.80) | 5.3(10.98) | 6.4(8.32) | 4.85(7.60) |
| PANASPOS | 30.45(6.39) | 29.20(7.19) | 30.45(7.29) | 28.95(7.70) |
| PANASNEG | 12.25(4.84) | 11.75(2.90) | 10.60(0.75) | 10.55(0.89) |
| VAS Nausea | 5.35(8.04) | 4.45(5.01) | 4.35(6.80) | 6.65(8.46) |
| VAS Dizziness | 4.55(4.77) | 11.90(16.13) | 5.35(8.91) | 7.20(9.66) |
| VAS Dry mouth | 11.35(14.73) | 8.90(12.23) | 11.05(15.32) | 7.80(13.88) |
| VAS Headache | 5.05(8.53) | 15.55(23.32) | 3.70(5.25) | 5.55(7.13) |
| VAS Alert | 46.55(33.77) | 44.30(28.68) | 56.35(30.33) | 50.15(29.75) |
| VAS Agitation | 9.75(9.05) | 7.80(9.40) | 9.45(15.80) | 8.60(17.69) |

BFS, Befindlichskeit Scale; VAS, Visual Analogue Scale; STAI, Spielberg State Trait Anxiety Inventory-State; PANAS: Positive and Negative Affect Schedule

**Table.3.** Mood, anxiety and side-effects ratings for day 2

|  |  |  |
| --- | --- | --- |
|  | DCS | Placebo |
| BFS | 12.95(12.22) | 14.9(16.42) |
| State Anxiety  (STAI) | 29.25(6.73) | 30.15(5.75) |
| VAS Happy | 70(18.83) | 63.9(16.20) |
| VAS Sad | 6.35(8.63) | 13.8(21.32) |
| VAS Interested | 62.35(24.14) | 58.65(21.44) |
| VAS Anxious | 7.10(12.19) | 7.75(8.82) |
| VAS Stressed | 13.30(18.44) | 13.50(16.10) |
| VAS Hostile | 4.80(10.39) | 7.20(13.16) |
| PANASPOS | 29.50(7.94) | 28.25(8.41) |
| PANASNEG | 11.40(2.28) | 11.10(1.41) |
| VAS Nausea | 3.25(3.57) | 3.7(6.60) |
| VAS Dizziness | 3.45(3.02) | 3.95(6.55) |
| VAS Dry mouth | 7.90(14.89) | 5.90(10.20) |
| VAS Headache | 5.10(6.68) | 3.40(5.47) |
| VAS Alert | 38.55(30.19) | 43.25(29.77) |
| VAS Agitation | 5.20(8.36) | 7.00(8.30) |

BFS, Befindlichskeit Scale; VAS, Visual Analogue Scale; STAI, Spielberg State Trait Anxiety Inventory-State; PANAS: Positive and Negative Affect Schedule